BRPI0905729A2 - "polipeptídeo antigênico recombinante, peptídeo antigênico recombinante, ácido nucléico e método para imunizar um indivíduo contra malária" - Google Patents

"polipeptídeo antigênico recombinante, peptídeo antigênico recombinante, ácido nucléico e método para imunizar um indivíduo contra malária"

Info

Publication number
BRPI0905729A2
BRPI0905729A2 BRPI0905729-3A BRPI0905729A BRPI0905729A2 BR PI0905729 A2 BRPI0905729 A2 BR PI0905729A2 BR PI0905729 A BRPI0905729 A BR PI0905729A BR PI0905729 A2 BRPI0905729 A2 BR PI0905729A2
Authority
BR
Brazil
Prior art keywords
recombinant antigen
immunizing
nucleic acid
individual against
against malaria
Prior art date
Application number
BRPI0905729-3A
Other languages
English (en)
Inventor
Avigdor Shafferman
Anat Zvi
John Fulkerson
Jerald C Sadoff
Original Assignee
Aeras Global Tb Vaccine Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeras Global Tb Vaccine Found filed Critical Aeras Global Tb Vaccine Found
Publication of BRPI0905729A2 publication Critical patent/BRPI0905729A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0905729-3A 2008-01-18 2009-01-12 "polipeptídeo antigênico recombinante, peptídeo antigênico recombinante, ácido nucléico e método para imunizar um indivíduo contra malária" BRPI0905729A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2199608P 2008-01-18 2008-01-18
PCT/US2009/030734 WO2009091692A2 (en) 2008-01-18 2009-01-12 Malaria vaccine compositions and constituents which elicit cell mediated immunity

Publications (1)

Publication Number Publication Date
BRPI0905729A2 true BRPI0905729A2 (pt) 2015-07-14

Family

ID=40885869

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905729-3A BRPI0905729A2 (pt) 2008-01-18 2009-01-12 "polipeptídeo antigênico recombinante, peptídeo antigênico recombinante, ácido nucléico e método para imunizar um indivíduo contra malária"

Country Status (6)

Country Link
US (1) US8728492B2 (pt)
EP (1) EP2249857A4 (pt)
JP (1) JP5573679B2 (pt)
CN (1) CN101969991A (pt)
BR (1) BRPI0905729A2 (pt)
WO (1) WO2009091692A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154199A1 (en) 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein
US9645147B2 (en) * 2012-11-09 2017-05-09 The United States Of America As Represented By The Secretary Of The Navy Recombinant polypeptide construct comprising Plasmodium falciparum circumsporozoite protein HLA class I restricted T-cell epitopes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78869T1 (de) * 1985-02-07 1992-08-15 Smithkline Beecham Corp Malaria-impfstoff.
BR8707471A (pt) * 1986-09-22 1988-09-13 Univ Emory Vacina e processo de preparacao
JP2002507397A (ja) 1998-03-13 2002-03-12 エピミューン，インコーポレイティド Ｈｌａ結合ペプチド及びその使用
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
JP5404990B2 (ja) * 2002-10-23 2014-02-05 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリアに対するワクチン接種の方法
CN101077416A (zh) * 2002-10-23 2007-11-28 葛兰素史密丝克莱恩生物有限公司 抗疟疾的疫苗接种方法
EP1569950B8 (en) 2002-12-06 2014-07-23 Epimmune Inc. Plasmodium falciparum antigens and methods of use
WO2006019427A2 (en) 2004-04-14 2006-02-23 The Governement Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Compositions and methods for prophylaxis, treatment and detection of malarial infections
WO2008074356A1 (en) 2006-12-21 2008-06-26 Stichting Biomedical Primate Research Centre Protein composition for inducing an immune response in a vertebrate comprising a plurality of protein variants covering the heterogeneity of a single antigen, ama1

Also Published As

Publication number Publication date
US8728492B2 (en) 2014-05-20
CN101969991A (zh) 2011-02-09
EP2249857A2 (en) 2010-11-17
WO2009091692A3 (en) 2009-10-08
US20110206714A1 (en) 2011-08-25
WO2009091692A2 (en) 2009-07-23
JP2011509672A (ja) 2011-03-31
JP5573679B2 (ja) 2014-08-20
EP2249857A4 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
BR112012022046A2 (pt) ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
CU24058B1 (es) Antagonistas de pcsk9
BRPI1011144A2 (pt) proteína precursora, sequência de ácido nucleico, cassete de expressão, vetor recombinante, método para produzir um peptídeo desejado, e, uso de um peptídeo anfifílico.
MX348071B (es) Variantes de fc.
BRPI0916964A2 (pt) polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BR112014012624A2 (pt) anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
BRPI0821447A2 (pt) Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
BR112012004221A2 (pt) "anticorpos, composição farmacêutica, uso do anticorpo, ácido nucleico, vetores de expressão, célula hospedeira procariótica e método para a produção de um anticorpo humanizado recombinante"
BRPI0808104A2 (pt) Métodos para preparar e para produzir um polipeptídeo, polipeptídeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, e, célula hospedeira recombinante
BR112012004823A2 (pt) composto de ligação, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos pra produzir um polipeptídeo e para intensificar uma resposta imune em um sujeiro humano, composição farmacêutica, e, anticorpo ou fragmento de ligação de antígeno
CL2013001124A1 (es) Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo.
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
DK1881845T3 (da) Nipah-virusvacciner
BRPI0810211A2 (pt) Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.
EP2010556A4 (en) HOMOGENEOUS ERYTHROPOETIN AND OTHER PEPTIDES AND PROTEINS, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
HK1215954A1 (zh) 蛋白、核酸、和抗體及其用途
BRPI0813242A2 (pt) Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
IL213189A (en) A vaccine containing avian influenza antigen, a method for vaccinating animals with the vaccine, antigen-encoded DNA and its uses
BRPI1013177A2 (pt) construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca
CO6690815A2 (es) Métodos y composiciones para inmunoterapia para enfermedad neural
WO2011153400A3 (en) Nasal immunization
BR112013012107A2 (pt) vacina multivalente, vetor recombinante, vetor de expressão, célula hospedeira recombinante, e, método para imunizar um animal contra filaríase
WO2009125231A3 (en) Anti-atheroma vaccine
EP1989316A4 (en) METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS
BR112012017532A2 (pt) "método para determinar um polipeptídeo com uma sequência de aminoácidos mutante, para produzir um poliptedo e uma imunoglobulina"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]